High Seroprevalence of HBV and HCV Infection in HIV-Infected Adults in Kigali, Rwanda

PLoS ONE

Volumn 8, Issue 5, 2013, Pages

  Rusine, John ^a,b,c   Ondoa, Pascale ^a   Asiimwe Kateera, Brenda ^b   Boer, Kimberly R ^a,b,d   Uwimana, Jean Marie ^c   Mukabayire, Odette ^c   Zaaijer, Hans ^a   Mugabekazi, Julie ^e   Reiss, Peter ^a   van de Wijgert, Janneke H ^a,f  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

^b INTERACT   (Rwanda)

^c National Reference Laboratory   (Rwanda)

^d ROYAL TROPICAL INSTITUTE   (Netherlands)

^e Centre Hospitalier Universitaire de Kigali   (Rwanda)

^f UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; EFAVIRENZ; HEPATITIS B SURFACE ANTIGEN; LAMIVUDINE; NEVIRAPINE; STAVUDINE; TENOFOVIR; VIRUS ANTIBODY; ZIDOVUDINE;

ADULT; AGING; ARTICLE; BLOOD SAMPLING; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HEPATITIS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C VIRUS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; POLYMERASE CHAIN REACTION; RWANDA; SEROPREVALENCE; VIRUS LOAD;

ADULT; ANTIGENS, CD4; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; COINFECTION; DISEASE PROGRESSION; FEMALE; HEPACIVIRUS; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HIV; HIV INFECTIONS; HUMANS; MALE; PREVALENCE; PROSPECTIVE STUDIES; RWANDA; SEROEPIDEMIOLOGIC STUDIES; VIRAL LOAD;

EID: 84878042175     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0063303     Document Type: Article

References (34)

1. Alter MJ, (2003) Epidemiology of hepatitis B in Europe and worldwide. J Hepatol 39(Suppl 1): S64-69.
2. Edmunds WJ, Medley GF, Nokes DJ, O'Callaghan CJ, Whittle HC, et al. (1996) Epidemiological patterns of hepatitis B virus (HBV) in highly endemic areas. Epidemiol Infect 117: 313-325.
3. Vardas E, Mathai M, Blaauw D, McAnerney J, Coppin A, et al. (1999) Preimmunization epidemiology of hepatitis B virus infection in South African children. J Med Virol 58: 111-115.
4. Lavanchy D, (2004) Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat 11: 97-107.
5. Shepard CW, Finelli L, Alter MJ, (2005) Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 5: 558-567.
6. Arshad M, El-Kamary SS, Jhaveri R, (2011) Hepatitis C virus infection during pregnancy and the newborn period - are they opportunities for treatment? J Viral Hepat 18: 229-236.
7. Burnett RJ, François G, Kew MC, (2005) Hepatitis B virus and human immunodeficiency virus co-infection in sub-Saharan Africa: a call for further investigation. Liver Int 25: 201-213.
8. Barth RE, Huijgen Q, Taljaard J, Hoepelman AI, (2010) Hepatitis B/C and HIV in sub-Saharan Africa: an association between highly prevalent infectious diseases. A systematic review and meta-analysis. Int J Infect Dis 14: e1024-e1031.
9. Hoffmann CJ, Thio CL, (2007) Clinical implications of HIV and hepatitis B co-infection in Asia and Africa. Lancet Infect Dis 7: 402-409.
10. Thio CL, Seaberg EC, Skolasky R Jr, Phair J, Visscher B, et al. (2002) HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet 360: 1921-1926.
11. Nunez M, Ramos B, Diaz-Pollan B, Camino N, Martín-Carbonero L, et al. (2006) Virological outcome of chronic hepatitis B virus infection in HIV-coinfected patients receiving anti-HBV active antiretroviral therapy. AIDS Res Human Retroviruses 22: 842-848.
12. Lok AS, Lai CL, Leung N, Yao GB, Cui ZY, et al. (2003) Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterol. 125: 1714-1722.
13. van Bommel F, Zollner B, Sarrazin C, Spengler U, Hüppe D, et al. (2006) Tenofovir for patients with lamivudine-resistant hepatitis B virus (HBV) infection and high HBV DNA level during adefovir therapy. Hepatol 44: 318-325.
14. Taylor LE, Swan T, Mayer KH (2012) HIV coinfection with hepatitis C virus: evolving epidemiology and treatment paradigms. Clin Infect Dis (Suppl 1): S33-S42.
15. Pirillo MF, Bassani L, Germinario EA, Mancini MG, Vyankandondera J, et al. (2007) Seroprevalence of hepatitis B and C viruses among HIV-infected pregnant women in Uganda and Rwanda. J Med Virol 79: 1797-1801.
16. Rwanda Ministry of Health (2011) National HIV Care and Treatment Guidelines, 2011.
17. Harania RS, Karuru J, Nelson M, Stebbing J, (2008) HIV, hepatitis B and hepatitis C coinfection in Kenya. AIDS 19: 1221-1222.
18. Nakwagala FN, Kagimu MM, (2002) Hepatitis B virus and HIV infections among patients in Mulago hospital. East Afr Med J 79: 68-72.
19. Di Bisceglie AM, Maskew M, Schulze D, Reyneke A, McNamara L, et al. (2010) HIV-HBV coinfection among South African patients receiving antiretroviral therapy. Antivir Ther 15: 499-503.
20. Firnhaber C, Viana R, Reyneke A, Schultze D, Malope B, et al. (2009) Occult hepatitis B virus infection in patients with isolated core antibody and HIV co-infection in an urban clinic in Johannesburg, South Africa. Int J Infect Dis 13: 488-492.
21. Laurent C, Bourgeois A, Mpoudi-Ngolé E, Kouanfack C, Ciaffi L, et al. (2010) High rates of active hepatitis B and C co-infections in HIV-1 infected Cameroonian adults initiating antiretroviral therapy. HIV Med 11: 85-89.
22. Otegbayo JA, Taiwo BO, Akingbola TS, Odaibo GN, Adedapo KS, et al. (2008) Prevalence of hepatitis B and C seropositivity in a Nigerian cohort of HIV-infected patients. Ann Hepatol 7: 152-156.
23. Diop-Ndiaye H, Toure-Kane C, Etard JF, Lô G, Diaw P, et al. (2008) Hepatitis B, C seroprevalence and delta viruses in HIV-1 Senegalese patients at HAART initiation (retrospective study). J Med Virol 80: 1332-1336.
24. Geretti AM, Patel M, Sarfo FS, Chadwick D, Verheyen J, et al. (2010) Detection of highly prevalent hepatitis B virus coinfection among HIV-positive persons in Ghana. J Clin Microbiol 48: 3223-3230.
25. Nebbia G, Garcia-Diaz A, Ayliffe U, Smith C, Dervisevic S, et al. (2007) Predictors and kinetics of occult hepatitis B virus infection in HIV-infected persons. J Med Virol 79: 1464-1471.
26. Shire NJ, Rouster SD, Rajici N, Sherman KE, (2004) Occult hepatitis B in HIV-infected patients. J Acquir Immune Defic Syndr 36: 869-875.
27. Chadwick D, Stanley A, Sarfo S, Appiah L, Ankcorn M, et al. (2013) Response to antiretroviral therapy in occult hepatitis B and HIV co-infection in West Africa. AIDS 27: 139-41.
28. Rao H-Y, Sun D-G, Yang R-F, Liu F, Wang J, et al. (2012) Outcome of hepatitis C infection in Chinese paid plasma donors: A 12-19-year cohort study. J Gastroenterol Hepatol 27: 526-532.
29. Seremba E, Ocama P, Opio CK, Kagimu M, Thomas DL, et al. (2010) Poor performance of hepatitis C antibody tests in hospital patients in Uganda. J Med Virol 82: 1371-1378.
30. Chadwick D, Ankcorn M, Sarfo F, Phillips R, Fox Z, et al. (2012) Outcomes of starting first-line antiretroviral therapy in hepatitis B virus/HIV-coinfected patients in Ghana. J Antimicrob Chemother: doi:10.1093/jac/dks333.
31. Hoffman CJ, Charalambous S, Martin DJ, Innes C, Churchyard GJ, et al. (2009) Hepatitis B virus infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis 49: 1268-1273.
32. Idoka J, Meloni S, Muazu M, Nimzing L, Badung B, et al. (2009) Impact of hepatitis B virus infection on human immunodeficiency virus response to antiretroviral therapy in Nigeria. Clin Infect Dis 49: 1268-1273.
33. Omland LH, Weis N, Skinhøj P, Laursen A, Christensen PB, et al. (2008) Impact of hepatitis B virus co-infection on response to highly active antiretroviral treatment and outcome in HIV-infected individuals: a nationwide cohort study. HIV Med 9: 300-306.
34. Ladep NG, Agbaji O, Agaba P, Badung P, Imade G, et al. (2007) Does immunological status affect the prevalence of Hepatitis C virus infection among HIV/AIDS patients? Niger J Med 16: 231-234.